Low-dose cyclosporine (CsA), starting at 1 mg/kg/day i.v. with early discontinuation, and four doses of methotrexate (MTX), was given to 82 consecutive leukaemic patients receiving HLA-identical sibling marrow transplants. Retrospective controls (n = 40) received CsA, starting at 5-7.5 mg/kg/day i.v., given for 1 year, and MTX. In the low-dose group, the risk of acute GVHD grades I-II was 78% as compared to 57% among the controls (P Ͻ 0.01). The risk of acute GVHD grades III-IV was 2% and 5%, respectively (NS). Chronic GVHD occurred in 60% in the low-dose group and 24% in the controls (P Ͻ 0.001). Extensive chronic GVHD did not differ between the groups (3% vs 6%). In multivariate analyses, low-dose CsA was the only factor associated with acute GVHD grades I-IV (P = 0.02). Significant risk factors for chronic GVHD included low-dose CsA (P = 0.002) and CML (P = 0.03). Transplant-related mortality at 3 years post-BMT was 22% and 19%, in the low-dose group and controls, respectively (NS). The probability of relapse was 26% in the low-dose group and 53% in the controls (P = 0.06). In multivariate analysis, high-dose CsA was the strongest risk factor for relapse (P = 0.03). The 3-year relapse-free survival was 58% in the low-dose group and 43% in the controls (P = 0.1).
In the present study, we aimed to compare the clinical outcome in leukaemic patients receiving low-dose CsA (starting at 1 mg/kg/day i.v.) aiming at 2 months' duration with retrospective controls receiving CsA, starting at 5-7.5 mg/kg/day i.v. and given for 1 year. The CsA doses and serum levels during the first 3 weeks after BMT have been reported to be crucial to the development of GVHD and the GVL effect. 9 Therefore we aimed to compare blood levels of CsA during this time period and analyse these in relation to the actual dose of CsA given and clinical outcome. We also wished to assess the impact of low-dose CsA on the incidence of GVHD and relapse in the presence of other, previously reported, potential risk factors.
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Materials and methods
Patients and donors
Eighty-two patients with leukaemia (AML, ALL and CML), receiving allogeneic stem cell grafts between February 1993 and June 1998, were included in the study group, all of them having HLA-A, -B and DR identical sibling donors and receiving the low-dose CsA protocol (starting at 1 mg/kg/day i.v., described below), in combination with MTX. This group was compared with retrospective controls (n = 40), transplanted between 1985 and 1993, and receiving CsA starting at 5-7.5 mg/kg/day i.v., in combination with MTX. The main clinical data of the patients (study group and controls) and their donors are depicted in Table 1 .
Conditioning
The majority of patients (n = 111) were conditioned with CY 120 mg/kg and TBI 10 Gy in one setting, as previously described. 22 Eleven patients were conditioned with a small BUCY regimen, consisting of BU 4 mg/kg p.o. in divided doses daily for 4 days, in combination with 120 mg/kg of CY (10 patients in the low-dose group and one patient among the controls). 23 Before November 1988, all patients received 8-12 mg MTX or 20 mg Ara-C intrathecally (IT) twice before BMT to prevent CNS leukaemia. Post-transplant, IT MTX was given from day 32 and every other week until day 102. After 1988, only patients with ALL, AML M4 and M5 and/or with a history of CNS disease were given this treatment. To patients with previous CNS disease, IT MTX was thereafter given every 8th week until 24 months post-BMT.
Immunosuppression and monitoring of CsA levels
All patients received CsA in combination with four doses of MTX i.v., 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11. CsA treatment was initiated i.v. on the day before BMT. Patients receiving low-dose CsA were given 1 mg/kg/day i.v. divided into two or three doses from day −1. On day 1, or as soon as the patient could take CsA orally, 3 mg/kg/day was given divided into two doses. From 2 months after BMT, in the absence of GVHD, the CsA dose was gradually tapered. Among the retrospective controls, CsA treatment was started at 5-7.5 mg/kg/day. 8 From day 1, or as soon as possible, CsA was given orally 12.5 mg/kg/day, and the highest tolerated CsA dose, with respect to serum creatinine levels, was given for 6 months. The dose was then gradually tapered and, in the absence of GVHD, discontinued after 1 year. In the low-dose group, CsA doses were adjusted according to blood levels and/or if toxicity was seen. We aimed at maintaining the CsA blood levels around 100 ng/ml. Three different methods for determining CsA blood levels have been used from 1985 up until today, without altering the reference values. 24 Between 1985 and April 1988, the Sandimmun kit (formerly manufactured by Sandoz, Basel, Switzerland) was used. From April 1988 until May 1997, we used the Cyclo-trac SP® (Incstar, Stillwater, MN, USA). Both of these methods were specific radioimmunoassays. Since May 1997, we use the EMIT 2000 Cyclosporine-specific Assay (Behring, Cupertino, CA, USA).
Grading and treatment of GVHD
Acute GVHD was graded from 0 to IV according to Glucksberg et al. 25 Grade I acute GVHD was treated with 2 mg/kg/day of prednisolone for 1 week and the dose was then tapered. In patients with progressive symptoms, prednisolone was continued for a longer period. In some severe cases, methylprednisolone (0.125-0.5 g/day), ATG, additional MTX or PUVA were also given. Chronic GVHD was graded as limited or extensive. It was initially treated with CsA and steroids. If a response was not seen, some patients received TLI, PUVA, and more recently extracorporeal PUVA. 26 
Statistical analysis
The results were analysed as of 15 October 1998, allowing for a median follow-up time of 38 months (range 5-68 months) in the low-dose group. Time to GVHD, relapse, survival, etc, were analysed by the life-table method with the log-rank test (Mantel-Haenzel), taking censored data into account. 27 Non-parametric analysis was performed with the Wilcoxon's signed rank test and the Mann-Whitney U test was used for paired and unpaired data, respectively. When analysing the risk of relapse and leukaemiafree survival (LFS), a separate subgroup analyses for patients in early and advanced disease was also performed.
When evaluating risk factors for acute GVHD, the logistic regression model was used in uni-and multivariate analyses. 28 All patients with a survival of at least 30 days were analysed and grades I-IV were regarded as the event. We evaluated the low-dose regimen among eight other risk factors, previously reported to be significant at our centre. 19 These included donor and recipient age, sex-match (including immunised female-to-male recipient), time to engraftment and pretransplant herpes virus serology for CMV, HSV, VZV and EBV (Table 2 ). When analysing risk factors for chronic GVHD, relapse, and leukaemia-free survival, the Cox regression model was used for the uni-and multivariate analyses. 29 Nineteen risk factors for chronic GVHD and six risk factors for relapse, previously reported to be significant in univariate analysis from our centre, were evaluated together with the low-dose regimen respectively (see Tables 3 and 4) . 20, 21 When evaluating age as a risk factor for chronic GVHD a continuous variable was used. This is in contrast with the analysis of risk factors for acute GVHD where an age cut-off at 17 years was used. The reason for this discrepancy is that the age factor is presented in the way that it was originally used in our previous two studies. 19, 20 For chronic GVHD, all patients surviving at least 90 days after BMT, and therefore at risk, were included in the analyses. Multivariate analysis of risk factors for relapse was performed both from day 90 and from the day of transplant.
Four risk factors, previously reported to correlate with inferior LFS, 21 were evaluated together with the low-dose regimen. These included acute GVHD grades II-IV, chronic GVHD, disease stage, pretransplant herpes virus serology for CMV, HSV, VZV and EBV, and TBI as compared to BU.
All CsA concentrations for the first 3 weeks after BMT were collected from patient records. The CsA dose and patient weight given on day 22 were also recorded. When analysing CsA concentrations, we calculated the geometric means for each individual patient for the first 3 weeks post-BMT. These means were then added, creating arithmetic means, weekly and overall for the first 21 days.
Results
CsA dose, serum levels and duration of treatment
In the low-dose group, patients had a median of seven CsA concentrations recorded during the first 3 weeks post-BMT (range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Among controls, the median number of CsA concentrations was 10 (range 0-17). In the low-dose group, where patients were to receive a p.o. dose of 3 mg/kg/day, the actual mean dose given on day 22 post-BMT was 4.6 mg/kg/day orally (range 0-11.8 mg/kg). Patients in the control group, who were to receive an initial p.o. dose of 12.5 mg/kg/day, were actually given a mean dose of 12.7 mg/kg (range 0-25.0 mg/kg) (P Ͻ 0.001).
Mean blood levels in the low-dose group for weeks 1, 2 and 3 were 152, 156 and 162 ng/ml, respectively. In the controls with a long CsA course, the corresponding mean blood levels of CsA were 518, 543 and 605 ng/ml (P Ͻ 0.001).
Patients in the low-dose group had a median duration of CsA treatment of 6.6 months (range 2.5-42.6), compared to 11.7 (range 0.7-48.8) months in the control group (P = 0.01).
Acute GVHD
Patients receiving low-dose CsA ran an actuarial risk of acute GVHD grades I-II of 78%, compared to 57% in the control group (P Ͻ 0.01) (Figure 1) . However, the incidences of acute GVHD grades III-IV were similar, 2% vs 5%, in the low-dose group and controls, respectively (NS) ( Table 5 ).
In logistic regression using univariate analysis, low-dose CsA, as compared to high-dose, was the only significant risk factor for acute GVHD grades I-IV (P = 0.02) ( Table 2 ). Donor age more than 17 years, as compared to younger donors, showed a trend towards significance (P = 0.08) and was therefore included in the subsequent multivariate analysis. However, only low-dose CsA maintained its significance in the multivariate analysis (P = 0.02) ( Table 4) .
Chronic GVHD
The actuarial risk of chronic GVHD was 60%, as compared to 24% in the controls (P Ͻ 0.001) (Figure 2) . However, as depicted in Table 2 , the risk of extensive chronic GVHD was the same in the two groups. In Cox regression univariate analysis, low-dose CsA (P Ͻ 0.01), recipient (P = 0.02) and donor age (P = 0.02) were significant factors associated with chronic GVHD. CML, as compared to acute leukaemia, and preceding acute GVHD (grades I-IV) were borderline significant (P = 0.06 and P = 0.06, respectively) and therefore were also included in the stepwise multivari- ate analysis (Table 3 ). Significant factors in multivariate analysis comprised low-dose CsA (P Ͻ 0.01) and CML (P = 0.03) ( Table 4) .
Transplant-related mortality (TRM), relapse and leukaemia-free survival (LFS)
TRM at 3 years was 22% and 19% in low-dose patients and controls, respectively (P = 0.9). Actuarial risk of relapse was 26% in the low-dose group and 53% in the control group (P = 0.06) (Figure 3) . Patients with early disease had a risk of relapse of 18% in the lowdose group as compared to 45% in the control group (P = 0.06). For patients with advanced leukaemia, the corresponding risks were 40% and 54%, in the low-dose group and the controls, respectively (P = 0.3). Low-dose CsA was included as a risk factor in the stepwise multivariate analysis, with other significant factors in the univariate analysis. These included absence of chronic GVHD (relative hazard, RH = 2.38, P = 0.02), a more advanced disease as compared to first complete remission or chronic phase (RH = 2.12, P = 0.03), and acute leukaemia as compared to CML (RH = 2.32, P = 0.04). Non-significant factors included TBI as compared to busulfan (P = 0.4), acute GVHD grade 0 as compared to grades I-IV (P = 0.09) and acute GVHD grades 0-I as compared to II-IV (P = 0.8). Significant factors in multivariate analysis comprised highdose CsA (P = 0.03), a more advanced disease (P = 0.04) and acute leukaemia (P = 0.05). Chronic GVHD did not maintain its significance in the multivariate analysis (data not shown). For this reason, multivariate analysis of risk factors for relapse, calculated from the day of transplant, is shown only (Table 4) . For 3-year LFS and actuarial patient survival the figures were 58% and 63% in the low-dose group, as compared to 43% and 50% among controls (P = 0.1 and P = 0.1, respectively) (Figure 4) . Patients with early disease had an LFS of 63% in the low-dose group as compared to 42% in the control group (P = 0.6). For patients with advanced disease, the probabilities of LFS were 45% and 25%, in the low-dose group and the controls, respectively (P = 0.06). The only factor that was significantly associated with a superior LFS, in uni-and multivariate analysis was the presence of chronic GVHD (P = 0.02).
Discussion
Patients receiving GVHD prophylaxis with low-dose CsA ran a significantly higher risk of developing acute GVHD grades I-II than did retrospective controls receiving a high CsA dose (78% vs 57%, respectively). Since the CsA dose was adjusted according to the blood levels of CsA, the mean doses given that we compared were 4.6 and 12.7 mg/kg/day orally in the two groups, respectively. In the low-dose group, we aimed to give 3 mg/kg/day orally. The increased dosage may be due to the fact that the CsA doses tended to increase in some patients developing acute GVHD. The median CsA level in blood was, therefore, also higher, 150 ng/ml, rather than 100, which was planned. CsA doses in the control group were given on the basis of highest tolerable dose with respect to serum creatinine levels. One may therefore assume that this corresponds approximately to the mean CsA dose of 12.7 mg/kg/day seen in the control group. In a previous report by Bacigalupo et al, 9 81 allografted patients with acute leukaemia were randomised to receive CsA 1 or 5 mg/kg/day i.v. from day −1 to day +20. The actuarial risk of developing acute GVHD grades II-IV did not differ significantly between the groups in their study. However, in a Cox model, when stratifying for age and CsA dose, the risk of acute GVHD grades II-IV was significantly higher among older patients (Ͼ20 years) and among patients receiving CsA 1 mg/kg/day. Multivariate analysis in our study showed that low-dose CsA was the only significant risk factor for developing acute GVHD grades I-IV. Unlike many other centres, we start to treat acute GVHD already at grade I. 4, 8 This may partly explain why there were no differences in severe acute GVHD (grades III-IV) between our two groups. Low-dose CsA was the strongest predictive factor for leukaemic relapse, when included in multivariate analysis (P = 0.03). These findings confirm those reported by Bacigalupo et al. 9 Concomitant treatment with cyclophosphamide and ciprofloxacin, during the pre-transplant conditioning, has been shown to correlate with an increased risk of relapse. 21 However, this risk factor was only present in the control group and could therefore not be evaluated separately in our analyses. Chronic GVHD was not significantly associated with an increased risk of relapse in multivariate analysis. One may speculate that when patients are given a significantly lower level of immunosuppression, the impact of chronic GVHD, as a risk factor for relapse, is of less importance. Interestingly, Bacigalupo et al reported no difference in the risk of chronic GVHD between the highand low-dose groups, in spite of a significant difference in relapse risk.
Figures for 3-year relapse-free survival and overall patient survival were in favour of our low-dose regimen, although differences between the groups did not reach significance. This may be due to the low number of patients. With more patients and a longer follow-up time, LFS may be significantly different, because TRM was the same in the two groups.
The duration of the CsA treatment was 6.6 and 11.7 months in the low-dose group and controls, respectively. We found that early discontinuation of CsA in the lowdose group was often complicated by ongoing mild acute GVHD, which prolonged the course of CsA. There have been reports where early discontinuation of CsA has not been associated with an increased risk of chronic GVHD. 16, 17 In contrast, a previous study from our centre showed an increased incidence of chronic GVHD, if CsA was discontinued after a median of 71 days, instead of 1 year. 18 A recent study showed that preceding acute GVHD is often of less importance for the development of chronic GVHD than was found earlier. 20 This may be due to the use of MTX combined with CsA, in contrast to monotherapy. In line with this, early discontinuation of CsA contributed to an increased risk of developing chronic GVHD, as shown in our study (60% among low-dose patients vs 24% among controls), hence not merely an effect of low CsA dosage. The optimal LFS in leukaemic patients is seen in patients who develop grade I acute GVHD. 30 Since 21% of the patients did not develop acute GVHD at all, there may still be reason to reduce the CsA dose further, and/or discontinue CsA earlier in some patients.
We conclude from these data that a low-dose regimen with CsA, starting at a dose of 1 mg/kg/day i.v., in combination with four doses of methotrexate (MTX), is an advan-tageous approach for recipients of HLA-identical sibling marrow transplants, with leukaemia. The risk of mild acute GVHD and limited chronic GVHD increased in the lowdose group. This enhances the GVL effect, which subsequently reduces the risk of leukaemic relapse post BMT. This regimen appears safe because the risk of acute GVHD grades III-IV, TRM and extensive chronic GVHD did not increase.
